Workshop I: Parkinson's disease and sleep--results of the group discussion.
The group agreed on the facts that unwanted sleep onset has been observed after non-ergot as well as ergot dopamine agonists, that patients on these drugs need to be warned, that patients who have experienced sleepiness already must not drive a car unless the dosage is lowered and sleepiness has vanished, that a genetic predisposition for narcoleptic cataplexy has to be ruled out, that predictors of so-called sleep attacks need to be explored individually with the help of sleepiness scales and collectively in a careful study, respectively.
Clarenbach
P
P
Dept. of Neurology, Ev. Johannes-Hospital, Bielefeld, Germany.
Greulich
W
W
Meinck
H M
HM
Rathey
B
B
Schipper
H
H
Lachenmayer
L
L
Werner
M
M
D015984:Causality; D002985:Clinical Protocols / Q000592:standards; D015259:Dopamine Agents / Q000009:adverse effects*; D004493:Education; D006801:Humans; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy*; D018579:Patient Selection; D012893:Sleep Wake Disorders / Q000139:chemically induced* / Q000145:classification / Q000503:physiopathology
D015259:Dopamine Agents